Topline findings Antenatal nipocalimab treatment was associated with low detectable drug levels in fetal, neonatal, and infant samples Infant IgG levels were low at birth but recovered to within normal ranges during early childhood No unusual or unexpected childhood illnesses were observed through 96 weeks of follow-up Protective antibody responses to routine childhood vaccinations were [...]